Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Myasthenia gravis associated with etanercept therapy. Muscle Nerve 2009 Jun;39(6):866-70

Date

04/18/2009

Pubmed ID

19373885

DOI

10.1002/mus.21280

Scopus ID

2-s2.0-67049145696 (requires institutional sign-in at Scopus site)   52 Citations

Abstract

Etanercept is an antagonist of tumor necrosis factor alpha that was developed to treat rheumatoid arthritis. In this report we present a patient who developed myasthenia gravis while taking etanercept and had resolution of symptoms after stopping it. This is the first report of this potential side effect and is of additional interest, because etanercept has been proposed as a treatment for myasthenia gravis.

Author List

Fee DB, Kasarskis EJ

Author

Dominic B. Fee MD Vice Chair, Professor in the Neurology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Aged
Antirheumatic Agents
Arthritis, Rheumatoid
Autoantibodies
Deglutition Disorders
Etanercept
Humans
Immunoglobulin G
Male
Muscle, Skeletal
Myasthenia Gravis
Neuromuscular Junction
Pharynx
Receptor Protein-Tyrosine Kinases
Receptors, Cholinergic
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha